Skip Navigation



Cardiovascular Research Advance Access [Corrected Proof] published online on July 6, 2009
Cardiovascular Research, doi:10.1093/cvr/cvp192
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
83/4/626    most recent
cvp192v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Laing, S. T.
Right arrow Articles by McPherson, D. D.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laing, S. T.
Right arrow Articles by McPherson, D. D.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Cardiovascular therapeutic uses of targeted ultrasound contrast agents

Susan T. Laing* and David D. McPherson

Division of Cardiology, Department of Internal Medicine, University of Texas Health Sciences Center-Houston, 6431 Fannin Street, MSB 1.246, Houston, TX 77030, USA

* Corresponding author. Tel: +1 713 500 6630; fax: +1 713 500 6556. E-mail address: susan.t.laing{at}uth.tmc.edu

The therapeutic use of ultrasound contrast agents (UCAs) is an emerging methodology with high potential for enhanced directed therapeutic gene, bioactive gas, drug, and stem cell delivery. Ultrasound-targeted microbubble destruction has already demonstrated feasibility for plasmid DNA delivery. Similarly, therapeutic ultrasound for thrombolysis treatment has been taken into the clinical setting, and the addition of UCAs for therapeutic delivery or enhanced effect through cavitation is a natural progression to this investigation. However, as with any new technique, safety needs to be first demonstrated before translation into clinical practice. This review article will focus on the development of UCAs for cardiac and vascular therapeutics as well as the limitations/concerns for the use of therapeutic ultrasound in clinical medicine in order to lay a foundation for investigators planning to enter this exciting field or for those who want to broaden their understanding.

KEYWORDS Ultrasound; Ultrasound contrast agents; Targeted delivery; Drug and gene delivery

Time for primary review: 41 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article

Contrast ultrasound molecular imaging: harnessing the power of bubbles
Jonathan R. Lindner
Cardiovasc Res 2009 83: 615-616. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
J. R. Lindner
Contrast ultrasound molecular imaging: harnessing the power of bubbles
Cardiovasc Res, September 1, 2009; 83(4): 615 - 616.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.